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The protein BigH3 is a cell-adhesion molecule induced by transforming growth
factor- (TGF-). It consists of four homologous repeat domains known as
FAS1 domains; mutations in these domains have been linked to corneal
dystrophy. The fourth FAS1 domain was expressed in Escherichia coli B834
(DE3) (a methionine auxotroph) and purified by DEAE anion-exchange and
gel-filtration chromatography. The FAS1 domain was crystallized using the
vapour-diffusion method. A SAD diffraction data set was collected to a
resolution of 2.5 A˚ at 100 K. The crystal belonged to space group P61 or P65 and
had two molecules per asymmetric unit, with unit-cell parameters a = b = 62.93,
c = 143.27 A˚,  =  = 90.0,  = 120.0.
1. Introduction
The protein BigH3 is an RGD-containing collagen-associated protein
in the extracellular matrix which is induced by transforming growth
factor- (TGF-) in various cells (Skonier et al., 1992, 1994; Bae et al.,
2002). It is involved in many cell processes such as cell growth,
differentiation, wound healing, angiogenesis and apoptosis (Kim et
al., 2003; Bae et al., 2002). It is also related to corneal, vascular and
renal diseases (O’Brien et al., 1996; Munier et al., 1997; Park et al.,
2004).
The protein BigH3 has a molecular weight of about 77 kDa, but
undergoes partial cleavage in the C-terminal region to generate 68–
70 kDa isoforms (Skonier et al., 1994). It has been detected in the
extracellular matrix (ECM) of various tissues. Most cells express
BigH3 at low levels, except for fibroblasts, in which expression is
higher. It binds to various extracellular matrix components, such as
fibronectin, laminin and some collagens (Billings et al., 2002; Kim,
Park et al., 2002). Recently, it has been reported that bovine collagen
VI is colocalized with BigH3 and that a disulfide bond may be formed
between the two (Hanssen et al., 2003). Moreover, it interacts with
integrins (31, 11 and V5) in various cell types (Kim, Park et
al., 2002; Bae et al., 2002; Ohno et al., 1999; Kim, Jeong et al., 2002)
through the RGD motif at the C-terminus of BigH3. These results
imply that BigH3 plays an important role in cell–cell interactions.
The protein BigH3 is composed of four homologous domains
known as FAS1 domains, which were originally found in Drosophila
melanogaster fasciclin 1, an insect neuronal cell-adhesion molecule.
FAS1 domains exist in many secreted and membrane-anchor proteins
from various organisms, including humans, bacteria, insects, plants
and yeast (Kawamoto et al., 1998). Generally, proteins containing
FAS1 domains have multiple tandem FAS1 domains along with other
types of domains. In humans, BigH3 is a secreted protein that has four
FAS1 domains.
Point mutations of BigH3 bring about several phenotypically
different corneal dystrophies: R555W is found in granular Groenouw
type I, R124C in Lattice type I, R124H in Avellino and R555Q in
Thiel-Behnke (Munier et al., 2002). In addition, the type of corneal
dystrophy determines the protein deposit type. For example, the
BigH3 mutant R555Q forms a protein deposit of curly fibres, whereas
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the R555W mutant gives rise to fuchsinophilic granular deposits
(Klintworth, 2003; Klintworth et al., 2004). This linkage means that a
specific mutation of BigH3 induces a specific type of corneal
dystrophy disease. Corneal dystrophy results in a reduction of visual
power and in eventual blindness owing to the accumulation of protein
deposits in the cornea. Development of a clinical therapy for corneal
dystrophy has been slow because it is not known how the protein
deposit accumulates progressively in the cornea (Klintworth et al.,
1998; Streeten et al., 1999). The structure of the FAS1 domains from
D. melanogaster have been determined (Clout et al., 2003), but this
study did not reliably explain the effect of the corneal dystrophy
mutations. In addition, an NMR structure of the fourth FAS1 domain
of human BigH3 (PDB code 1x3b) has recently been determined,
although no analysis of the structure has been reported to date. Thus,
it is not clear why mutations induce the accumulation of pathological
amyloid deposits and result in corneal dystrophies. To answer this
question, we tried to determine the structure of the fourth FAS1
domain of human BigH3. This study reports the crystallization and
preliminary analysis of the fourth FAS1 domain of human BigH3. We
expressed the SeMet-substituted protein and obtained a crystal that
diffracted to 2.5 A˚. The structure of the fourth FAS1 domain of
human BigH3 may provide new information about the physical and
biochemical mechanisms of BigH3 protein aggregation caused by the
R555Q and R555W mutations.
2. Materials and methods
2.1. Protein expression
DNA fragments corresponding to the fourth FAS1 domain (amino
acids 502–636) were inserted into the pRSET(A) vector (Invitrogen).
In order to obtain SeMet-substituted protein, the cloned DNA was
transformed into Escherichia coli B834 (DE3), which is a methionine
auxotroph. The transformed cells were cultured in M9 medium
containing an amino-acid mixture [0.1 g lysine, threonine and
phenylalanine, 0.05 g leucine, isoleucine, valine and l-(+)-seleno-
methionine] at 310 K until the OD600 reached 0.5. The protein was
expressed by adding 1 mM isopropyl -d-1-thiogalactopyranoside
(IPTG) at 310 K for 4 h. The cells were harvested by centrifugation at
3500 rev min1 for 10 min at 277 K.
2.2. Protein purification
Harvested cells were suspended in lysis buffer (20 mM Tris–HCl
pH 8.0) and disrupted by sonication. The lysate was centrifuged at
12 000 rev min1 for 15 min at 277 K. The supernatant obtained was
loaded onto a DEAE anion-exchange column equilibrated with lysis
buffer. The resin was washed with the same buffer and the FAS1
domain was eluted with a salt gradient from 0 to 0.3M NaCl. The
presence of the protein was confirmed by SDS–PAGE of each frac-
tion. For further purification, collected fractions were loaded onto a
gel-filtration column (Superdex200, Amersham Bioscience) with
buffer A (20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM -mercapto-
ethanol). The purified protein was concentrated to 20 mg ml1 using
a Centricon device with a10 kDa pore size (Amicon Ultra, Millipore).
2.3. Crystallization and X-ray diffraction
The initial crystallization conditions were determined by screening
solutions using the microbatch method (Index HT kit, Hampton
Research). The optimal crystallization conditions were obtained
using the vapour-diffusion method at 290 K. A crystal (Fig. 1) was
grown in a mixture containing equal volumes of the protein and
reservoir buffer (4.0M sodium formate pH 7.0) over 3–4 weeks.
Crystals were transferred to a cryoprotectant composed of reser-
voir solution with 20%(v/v) ethylene glycol prior to data collection.
Data were collected on the 4A MXW beamline at Pohang Light
Source (PAL), South Korea. SAD data were collected from an
SeMet-incorporated protein crystal at 100 K. A total of 270 images
(0–270) were obtained using a 1 oscillation width at the selenium
peak wavelength (0.97939 A˚) without an inverse-beam experiment.
All collected data were indexed, integrated and scaled with DENZO
and SCALEPACK from the HKL-2000 program package (Otwi-
nowski & Minor, 1997).
3. Results and discussion
From the diffraction data, the SeMet-substituted fourth FAS1 domain
crystal belongs to space group P61 or P65 and has unit-cell parameters
a = b = 63.090, c = 143.374 A˚,  =  = 90.0,  = 120.0. The diffraction
data set had a resolution range of 50–2.5 A˚ with 100% completeness
and an Rsym of 10.7% (Table 1). There were two molecules per
asymmetric unit and the Matthews coefficient VM was calculated to
be 2.93 A˚3 Da1, which corresponds to a solvent content of 58%.
The FAS1-domain structure from D. melanogaster and the NMR
structure of the fourth domain of human BigH3 were used as models
to solve this structure by molecular replacement. However, initial
molecular-replacement attempts were not successful. Therefore, we
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Figure 1
Crystal of the SeMet-substituted fourth FAS1 domain of human BigH3. The
dimensions of the crystal are approximately 0.1  0.4  0.02 mm.
Table 1
Diffraction statistics.
Values in parentheses are for the highest resolution shell.
Wavelength (A˚) 0.97939
Resolution (A˚) 50–2.5
Space group P61 or P65
Unit-cell parameters a = 62.93, c = 143.29
Total/unique reflections 190248/11191
Completeness (%) 100 (100)
Rsym† (%) 10.7 (60.7)
Average I/(I) 35.38 (5.04)
Resolution range for phasing 50–3.5
Redundancy 16.9 (15.5)
Anomalous signal-to-noise
P61 1.99 (3.54)
P65 1.99 (3.54)
Figure of merit
P61 0.34 (0.33)
P65 0.33 (0.32)
† Rsym =
P jIobs  Iavgj=
P
Iobs, where Iobs is the observed intensity of an individual
reflection and Iavg is the average over symmetry equivalents.
attempted to use the SAD method to solve the phase problem.
Because the fourth FAS1 domain of BigH3 contains four methionine
residues, we expected to find eight selenium sites using the programs
SOLVE (Terwilliger & Berendzen, 1999) and SHELX (Sheldrick &
Schneider, 1997), but only four selenium sites were found, giving
partial phase information that was not sufficient for manual tracing.
Table 1 shows phase information including the anomalous signal-to-
noise and figure of merit. Structure determination of this protein is
currently in progress using the molecular-replacement method with
the partially phased map.
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